Skip to main content
. 2021 Apr 8;35(5):1229–1242. doi: 10.1038/s41375-021-01238-w

Fig. 1. Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) patients.

Fig. 1

Upper diagram—CML effects on untreated immune cells. Lower diagram—effects on immune cells after TKI treatment, including cytotoxic T-cells (CTLs), natural killer (NK) cells, dendritic cells (DCs) and plasmacytoid DCs (pDCs), myeloid-derived suppressor cells (MDSCs), regulatory T-cells (Tregs), mesenchymal stromal cells (MSCs) and B-cells. LAAs leukemia-associated antigens, G-MDSCs granulocyte-like MDSCs, PD1 programmed death 1, TFR treatment-free remission, DMR deep molecular response (or MR4; BCR-ABL1 ≤ 0.01%), MR4.5 molecular response4.5 (BCR-ABL1 ≤ 0.0032%), CCR complete cytogenetic remission. Illustration was created with BioRender.com.